Compare SWKH & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SWKH | ELTX |
|---|---|---|
| Founded | 1996 | 2011 |
| Country | United States | United States |
| Employees | 9 | N/A |
| Industry | Diversified Financial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 198.4M | 198.7M |
| IPO Year | N/A | 2014 |
| Metric | SWKH | ELTX |
|---|---|---|
| Price | $15.90 | $10.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $18.00 | $18.00 |
| AVG Volume (30 Days) | 104.8K | ★ 117.1K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.29 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,301,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.18 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.32 | $4.89 |
| 52 Week High | $17.90 | $14.93 |
| Indicator | SWKH | ELTX |
|---|---|---|
| Relative Strength Index (RSI) | 32.19 | 43.89 |
| Support Level | $14.69 | $9.99 |
| Resistance Level | $17.08 | $11.23 |
| Average True Range (ATR) | 0.37 | 0.89 |
| MACD | -0.05 | -0.16 |
| Stochastic Oscillator | 12.06 | 11.42 |
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.